지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Background: Biologic disease-modifying antirheumatic drugs (bDMARDs) extend the treatment choices for rheumatoid arthritispatients with insufficient response or intolerance to conventional DMARDs (cDMARDs). These agents have considerable efficacycompared with conventional DMARDs, but only a few head-to-head comparisons among these agents have been performed. Theobjective of this systematic review and network meta-analysis (NMA) was to compare the relative efficacy of Certolizumab withconventional DMARD to licensed bDMARD with cDMARD therapy for patients who failed to prior cDMARD treatment under thecondition of the reimbursement coverage criteria in Korea. Methods: A systematic review was conducted using MEDLINE andCochrane library. Key endpoints were the American College of Rheumatology (ACR) responses of 20/50/70 at six months. Bayesianoutcomes were calculated as median of treatment effect, probability of the best, Odds Ratio (OR) and probability that OR wasgreater than one. Results: Compared with other bDMARDs, Certolizumab were associated with higher or comparable ACR responserates; in ACR20, the OR (probability of OR>1) was 2.08 (92.6%) for Adalimumab, 1.86 (85.7%) for Etanercept, 1.89 (79.5%) forGolimumab, 2.36 (92.1%) for Infliximab, 1.79 (87.0%) for Abatacept, 1.74 (80.8%) for Rituximab and 1.82 (86.8%) for Tocilizaumab. InACR50 and ACR70, the ORs did not present significant differences. Conclusion: Certolizaumab with cDMARD was more effective orcomparable than other bDMARDs in patients who failed prior cDMARD treatment.
목차
등록된 정보가 없습니다.
참고문헌 (21)
참고문헌 신청
/ / Health Insurance Review & Assessment Service
Adams R. / 2010 / Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis / Pharmacoeconomics 28 : 477 ~ 487
Furst DE. / 2003 / Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheuma
Guyot P. / 2012 / Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in t
Jansen JP. / 2008 / Bayesian meta-analysis of multiple treatment comparisons : an introduction to mixed treatment comparisons / Value Health 11 : 956 ~ 964
Adams R. / 2010 / Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis / Pharmacoeconomics 28 : 477 ~ 487
Furst DE. / 2003 / Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheuma
Guyot P. / 2012 / Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in t
Jansen JP. / 2008 / Bayesian meta-analysis of multiple treatment comparisons : an introduction to mixed treatment comparisons / Value Health 11 : 956 ~ 964
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Treatment Sequence After Initiating Biologic Therapy for Patients With Rheumatoid Arthritis in Korea: A Nationwide Retrospective Cohort Study
대한류마티스학회지
2023 .01
-
Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?
대한류마티스학회지
2022 .10
-
Use of Disease-modifying Antirheumatic Drugs After Cancer Diagnosis in Rheumatoid Arthritis Patients
대한류마티스학회지
2022 .07
-
류마티스관절염의 약물치료
대한의사협회지
2017 .01
-
류마티스관절염의 생물학적제제치료
대한의사협회지
2021 .01
-
KOBIO, the First Web-based Korean Biologics Registry Operated With a Unified Platform Among Distinct Disease Entities
대한류마티스학회지
2021 .10
-
Risk of Herpes Zoster in Patients with Rheumatoid Arthritis Undergoing Biologic Disease-Modifying Therapy
대한류마티스학회지
2017 .01
-
Real-world effectiveness of a single conventional disease-modifying anti-rheumatic drug (cDMARD) plus an anti-TNF agent versus multiple cDMARDs in rheumatoid arthritis: a prospective observational study
대한류마티스학회지
2024 .04
-
피하주사로 투여하는 생물학적 항류마티스 제제의 비용 최소화 연구
한국임상약학회지
2016 .01
-
The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea: Results of a Korean Expert Consensus
대한류마티스학회지
2020 .01
-
Pregnancy Outcomes Associated With Biologic Agent Exposure in Patients With Several Rheumatic Diseases and Inflammatory Bowel Diseases
Journal of Korean Medical Science
2023 .06
-
건선의 생물학제제 교체치료
대한건선학회지
2018 .01
-
Positive Effects of Biologics on Osteoporosis in Rheumatoid Arthritis
대한류마티스학회지
2023 .01
-
류마티스관절염의 야누스인산화효소억제제 치료
대한의사협회지
2021 .01
-
Biologic mesh
대한외과학회 학술대회 초록집
2016 .11
-
Use of Anti-TNF Alpha Blockers Can Reduce Operation Rate and Lead to Growth Gain in Pediatric Crohn's Disease
Pediatric Gastroenterology, Hepatology & Nutrition
2019 .01
-
Association between Treatment with Biologic Agents and the Incidence of Herpes Zoster in Rheumatoid Arthritis
대한류마티스학회지
2017 .01
-
Diagnosis and Treatment of Inflammatory Joint Disease
Hip and Pelvis
2017 .01
-
중등도와 중증의 건선환자에서 생물학제제 치료 후 치료 만족도에 대한 평가
대한건선학회지
2021 .12
이 논문의 저자 정보
최근 본 자료
댓글(0)
0